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OBJECTIVES: The purpose of this study was to compare the
cost of the oral therapy with capecitabine + IV cisplatin (XP)
against standard IV therapy with 5-ﬂuoruracil + cisplatin (FP) as
ﬁrst-line treatment for patients with advanced gastric cancer
(AGC). METHODS: A cost minimization analysis was con-
ducted based on clinical data from the phase III trial of Kang
et al. 2006. In this trial patients were treated until disease pro-
gression, which corresponded to 5.22 cycles of chemotherapy for
XP and 4.56 cycles for FP (Kang et al. 2006). Progression free-
survival and overall survival with XP was non-inferior to FP.
Therefore, we assumed that both treatments compared in this
study had the same effectiveness. We considered direct costs
(drugs, administration of drug, physician fees), non-medical
direct costs per patient (transportation to hospital) and indirect
costs (hours of absence from work). A Delphi panel was con-
ducted to identify local practices and resources use in Brazil.
Costs such as medical payment, pre and post medication and
administration were also included. One-way and multi-way sen-
sitivity analyses were performed for testing robustness of results.
RESULTS: Total cost per patient in the XP group (R$14,247)
was signiﬁcantly lower than the total cost per patient in the FP
group (R$15,649). As a result of the additional visits for infusion
of 5-FU, FP patients incurred greater indirect costs in terms of
lost time. The sensitivity analysis conﬁrmed the robustness of the
results. Capecitabine beneﬁts AGC patients by reducing the
number of infusion visits and time spent receiving IV adminis-
tration, and would produce signiﬁcant direct medical cost
savings. CONCLUSION: Findings of this cost-minimization
analysis suggest XP as a cost-saving alternative from the Brazil-
ian societal perspective.
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FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROMTHE
PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL
Stefani S1, Saggia MG2, Santos EA2
1UNIMED and Instituto do Câncer Mãe de Deus, Porto Alegre, RS,
Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil
OBJECTIVES: To perform a cost-minimisation and budget
impact analysis of erlotinib versus docetaxel or pemetrexed for
the treatment of patients with advanced NSCLC who have failed
previous chemotherapy. METHODS: In the absence of head-
to-head clinical trial data for erlotinib versus docetaxel or
pemetrexed, equivalent efﬁcacy was assumed for the three inter-
ventions; indirect comparisons of phase III trial results suggest
that this was a conservative assumption. We developed a cost-
minimisation and budget impact model for cost comparison of
these three treatments based on the results of the BR.21 study of
erlotinib, and pivotal trials for docetaxel and pemetrexed, adopt-
ing a Brazilian private payer perspective. A 126-day timeframe
was used for the comparison, based on the progression-free
survival observed in the BR.21 study. A Delphi panel was con-
ducted to identify local practices and their associated costs in
Brazil. Other costs such as medical payment, pre- and post-
medication, and administration were also included. One-way
and multi-way sensitivity analyses were performed to assess the
robustness of the outcomes. Discounting was not included due to
the short-term perspective of the analysis. RESULTS: Total costs
were R$26,825 for erlotinib, R$42,284 for docetaxel and
R$79,841 for pemetrexed. The cost-savings observed for erlo-
tinib were due to lower acquisition costs (R$26,795 versus
R$40,217 for docetaxel and R$78,911 for pemetrexed) and its
more favourable tolerability proﬁle. Sensitivity analyses con-
ﬁrmed the robustness of the results obtained. The budget impact
analysis showed savings in the ﬁrst year after incorporation of
erlotinib starting from R$3,576,931 in a conservative scenario,
and reaching R$32,192,379 at the upper limit. CONCLUSION:
The ﬁndings of this cost-minimisation analysis suggest that erlo-
tinib is a cost-saving alternative under the private health care
system perspective in Brazil.
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OBJECTIVES: A cost-minization analysis compared costs and
medical resources of the treatment of pegﬁlgastrim (PF) versus
ﬁlgastrim (F), for the prophylaxis of chemotherapy (CT)-induced
febrile neutropenia (FN) in high-risk stage II-IV breast cancer
patients. METHODS: Two important clinical trials compared
the efﬁcacy of pegﬁlgrastim versus ﬁlgrastim: Holmes et al. 2002
and Green et al. 2003. Those studies have shown that a single
dose of pegﬁlgrastim corresponds, in terms of severe neutropenia
time reduction, to approximately 11 doses of ﬁlgrastim. Data of
FN incidence was provided by a retrospective study based on a
phase III trial (Green et al. 2002). According to that study, peg-
ﬁlgastrim arm was more effective to decrease the FN incidence,
consequently, hospitalization (PF 18% vs. F 31%), blood trans-
fusion (PF 4% vs. F 25%) and IV antibiotics (PF 17% vs. F
21%). For the base case a patient with 72.8 Kg was considered.
A panel with Brazilian experts was conducted to determine local
practice for prophylaxis of FN and in the treatment of patients
who develop FN. Only direct costs were considered: drugs
administration, hemograms, daily hospital costs, transfusion and
antibiotics costs. As per clinical trials the time horizon considered
was 4 months therefore discounting was not applied. This assess-
ment was undertaken from the Brazilian payer perspective.
RESULTS: Acquisition drug costs for pegﬁlgastrim were higher
than ﬁlgastrim (R$ 5010 vs. R$ 447). However, pegﬁlgastrim
treatment was cost-saving (R$ 4631) due to the reduction in the
number of administrations per CT cycle (1 vs. 11). One-way
sensitivity analysis was conducted and results were robust. CON-
CLUSION: Findings suggest pegﬁlgastrim as a cost-saving
therapy for the prophylaxis of CT-induced FN under the payer
perspective in Brazil.
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OBJECTIVES: A cost minimization analysis was developed to
compare the costs of intra-venous biphosphonates therapies
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available in Brazil for preventing skeletal events (SE) in breast
cancer patients with bone metastasis. METHODS: Indirect
comparison of different clinical trials published do not allow us
to consider that exist an efﬁcacy difference among ibandronate
acid, zoledronic acid and pamidronic acid (e.g.: Body et al.
2004; Rosen et al. 2003; Theriault et al. 1999). In our analysis
only direct costs were considered. The indirect costs of treating
SE were not estimated. For direct costs calculations we assumed
the reduction in analgesics usage reported by De Cock et a.
2005 (Ibandronic acid: 7% reduction vs. Comparators: 3%
reduction). The time horizon of the analysis was 14 months
which represents the average overall survival of patients
(Hotton J et al. 2004). Therefore discounting was not applied.
The payer perspective was adopted under the Brazilian setting.
A one-way sensitivity analysis was conducted. RESULTS:
Results show that ibandronic acid offers the lowest treatment
cost, followed by pamidronic acid and zoledronic acid (R$
10,301, R$ 10,906 and R$ 12,829). Results were sensitive to
drug prices. CONCLUSION: Results suggest ibandronate acid
as a cost-saving alternative with better safety proﬁle when com-
pared to zoledronic acid and pamidronic acid under the Private
Healthcare System perspective in Brazil.
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OBJECTIVES: Navelbine® (Vinorelbine) Oral is an orally
administered formulation of chemotherapy (CT) recently intro-
duced in Italy in the treatment of NSCLC (Non Small Cell Lung
Cancer) and Metastatic Breast Cancer. The purpose of this study
is to evaluate the economic consequences of the impact on phar-
macy, nursing time and patient waiting time of a switch from IV
to oral CT in the treatment of NSCLC. METHODS: Cost-
minimisation analysis was developed in order to evaluate the
times required to deliver IV vinorelbine and oral vinorelbine. The
comparison was made in two settings with different patient path-
ways, in the Cancer Center Unit of Istituto Nazionale dei Tumori,
Milan and Azienda Ospedaliera di Busto Arsizio, Varese. A stop-
watch was used to time elements of essential processes (phar-
macy preparation and chemotherapy administration) and patient
waiting time for the delivery of a single dose of chemotherapy, in
order to build an hypothetic diagnostic and therapeutic pathway
and to describe different phases, times and costs for each formu-
lation. RESULTS: Administration of Vinorelbine Oral was less
time consuming in both Cancer Centres. In the base case sce-
nario, total costs were €171.75 for Oral Vinorelbine (60 mg/m2)
versus €214.84 for IV Vinorelbine (25 mg/m2); for Oral Vinorel-
bine (80 mg/m2) versus IV Vinorelbine (30 mg/m2) costs were
€240.46 and €232.82 respectively. Productivity loss and patient
waiting time were key drivers to our cost minimisation analysis.
Results were submitted to a Sensitivity Analysis. CONCLU-
SION: Delivery of oral CT is less resource intensive and time
consuming than IV CT and reduces overall patient waiting in
hospital. A switch from Vinorelbine IV to Oral formulation with
home administration could increase the capacity of the Day-
Hospital Unit, the number of prescriptions prepared by phar-
macy and thereafter a reduction of the patient waiting list wich is
associated with a global cost reduction.
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OBJECTIVES: The purpose of this study was to compare the
costs of the drug, drug administration and managing of adverse
events (AEs) using erlotinib, docetaxel and pemetrexed as second
line therapy in non-small cell lung cancer (NSCLC), in the Italian
hospital setting. METHODS: Since a clinical study comparing
the three therapies is not available, the major clinical ﬁndings
from randomized trials of each drug were used showing that all
three chemotherapies have comparable efﬁcacy results. Therefore
a cost-minimization analysis was performed. Costs from the
hospital perspective were calculated according to Italian clinical
practice. Consumption of each chemotherapy was based on
respective clinical trial, while to estimate the resources used in the
AEs and for the drug administration a Delphi panel of experts
was structured. In order to allow a comparison between an oral
daily therapy (erlotinib) and infusion therapies administered
every 21 days (docetaxel and pemetrexed), costs were computed
on a monthly base. RESULTS: The total per-patient cost for
erlotinib was €1669, €2569 for docetaxel and €3324 for pemetr-
exed for one month therapy from the hospital perspective. The
cost of AEs represents the 8%, 18%, and 3% of the total cost for
erlotinib, docetaxel and pemetrexed. Sensitivity analysis showed
that no reasonable changes in the quantity and cost of services
reduced the savings associated with erlotinib by more than 33%.
CONCLUSION: A cost-minimization analysis was performed to
assess the cost of three second line chemotherapies in non-small
cell lung cancer. The less costly alternative was erlotinib which
could produce savings between 40% anD 50% of total hospital
costs in Italy.
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OBJECTIVES: To value the use of resources and costs linked
with different presentations of oxaliplatin: lyophilised powder
and concentrated solution. METHODS: A cost-minimization
analysis was conducted with the Spanish hospital’s perspective.
Time consumption and use of resources linked with the prepa-
ration of the products were obtained from a study conducted in
a cancer center in France. The preparation was performed
according to standard clinical practice and several measures were
taken to avoid any bias in the process. Spanish unitary costs were
applied to all resource measures: technicianxs time, consumables
(needles, syringes, water, tampon gauze and air intake), using
cost data from a Spanish oncology centre. RESULTS: The new
concentration solution of oxaliplatin achieves a 56% reduction
in preparation time, saving 139 seconds compared with the lyo-
philised powder (p < 0.001) and also is linked to less use of
consumables. Monetary savings linked to preparation time and
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